COO Share Price Performance
US$82.75
-9.77 (-10.56%)
8.6% undervalued intrinsic discount
US$90.50
Fair Value
Price US$82.75
AnalystConsensusTarget US$90.50
Fair ValueUS$90.50
Share Pricen/a
The Cooper Companies, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 29 Fair Values set on narratives written by author
COO Community Narratives
AN
Fair Value US$90.5 8.6% undervalued intrinsic discount
COO: Share Buybacks And Merger Potential Will Drive Undervalued Stock Higher
0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
COO: Share Buybacks And Merger Potential Will Drive Undervalued Stock Higher
Key Takeaways Resolving production constraints and launching innovative contact lens products position the company for strong revenue growth and market share gains, especially in premium and specialty segments. Automation, successful acquisitions, and cost discipline are expected to boost operating efficiency, margins, and free cash flow, supporting shareholder returns.Read more
222
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
AN
US$90.5
8.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
5.52% p.a.
Profit Margin
15.53%
Future PE
28.29x
Price in 2028
US$113.84
Trending Discussion
Recently Updated Narratives
AN
COO: Future Returns Will Balance Buybacks With Activist Governance Pressure
Fair Value: US$90.5 8.6% undervalued intrinsic discount
15 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
The Cooper Companies, Inc. Key Details
About COO
- Founded
- 1958
- Employees
- 15000
- CEO
- WebsiteView website
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women’s health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
